menu
    • menu

    Company profile for Immorna

    NEW Drugs in Dev: 4
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Immorna is utilizing multiple RNA platforms, including conventional, self-replicating and circular RNA. Since its founding in 2019, Immorna has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, wit...
    Immorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Immorna is utilizing multiple RNA platforms, including conventional, self-replicating and circular RNA. Since its founding in 2019, Immorna has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmornaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Research Triangle Park, NC
    Telephone
    Telephone
    +1 (984) 888-0460
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immorna.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RNA Startups Enter Clinic In Autoimmune CAR-T Race
    RNA Startups Enter Clinic In Autoimmune CAR-T Race

    15 Apr 2026

    // ENDPOINTS

    https://endpoints.news/in-vivo-car-t-race-for-autoimmune-grows-as-two-rna-startups-enter-the-clinic/

    ENDPOINTS
    15 Apr 2026
    Share Share
    Immorna Receives Grant For MRNA RSV Vaccine Development From Gates Foundation
    Immorna Receives Grant For MRNA RSV Vaccine Development From Gates Foundation

    27 Aug 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=172114&sid=2

    PHARMABIZ
    27 Aug 2024
    Share Share
    Immorna Gets FDA Clearance For JCXH-211 IV Phase 1/2 Study In Solid Tumors
    Immorna Gets FDA Clearance For JCXH-211 IV Phase 1/2 Study In Solid Tumors

    08 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immorna-biotherapeutics-receives-us-fda-ind-clearance-to-conduct-phase-12-study-of-jcxh-211-iv-as-monotherapy-and-in-combination-with-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-302190627.html

    PR NEWSWIRE
    08 Jul 2024
    Share Share
    Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105
    Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105

    09 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immorna-receives-ind-clearance-to-conduct-a-phase-1-study-of-jcxh-105-a-self-replicating-rna-based-shingles-vaccine-301716011.html

    PR NEWSWIRE
    09 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search